does a tesamorelin CJC ipamorelin blend have a one-week half-life?
5.8 to 8.1 days belongs to verified CJC-1295 with DAC in a component study. it is not a measured property of an unresolved three-way vial.
verdict: unsupported until identity is verified, and unmeasured even then (component data / fixed-blend evidence absent)
quick answer
no fixed-blend PK study exists. A week-scale value can describe only CJC-1295 with DAC when that exact component is confirmed. Modified GRF(1-29) or a no-DAC label cannot inherit it, and neither can the complete blend.
the evidence
the components have separate evidence records. (supported)
Tesamorelin has a single-ingredient FDA label. CJC-1295 with DAC and ipamorelin have early human pharmacology studies. Those records remain component-specific.
two GHRH agonists are not three complementary pathways. (gap)
Tesamorelin and CJC both act through the GHRH receptor. Whether combining them adds benefit or only exposure has not been tested in this fixed blend.
identity blocks the calculation. (risk)
The CJC variant, component forms, amounts, and vial ratio must be verified before even component-level interpretation. No combined dose, schedule, reconstitution, or half-life is validated.
bottom line
the longest component is not the measured half-life of a mixture.
scores
- component PK: 70 — CJC-DAC and ipamorelin have separate records
- blend identity: 4 — CJC variant and component forms unresolved
- fixed-blend PK: 0 — no study located
- protocol validity: 0 — component schedules cannot be added together
keep reading
- open blend entry — identity and formulation gate
- open CJC-1295 entry — DAC versus no-DAC distinction
- growth-hormone category — component-level evidence map
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.
